Medicus Pharma (NASDAQ:MDCX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $27.00 price objective on the stock. D. Boral Capital's target price would indicate a potential upside of 288.49% from the stock's current price.
A number of other analysts have also recently weighed in on the stock. Maxim Group raised their price objective on shares of Medicus Pharma from $10.00 to $20.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. D Boral Capital raised shares of Medicus Pharma to a "strong-buy" rating in a report on Monday, April 14th. One analyst has rated the stock with a sell rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $23.50.
Read Our Latest Research Report on Medicus Pharma
Medicus Pharma Stock Down 4.7%
NASDAQ:MDCX traded down $0.34 during mid-day trading on Thursday, hitting $6.95. The stock had a trading volume of 188,390 shares, compared to its average volume of 84,453. The firm's 50-day simple moving average is $4.45. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $8.94.
Medicus Pharma (NASDAQ:MDCX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). On average, equities analysts anticipate that Medicus Pharma will post -1.14 EPS for the current year.
Insiders Place Their Bets
In related news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of Medicus Pharma stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $7.72, for a total value of $579,000.00. Following the transaction, the insider now directly owns 3,248,741 shares in the company, valued at $25,080,280.52. This trade represents a 2.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Institutional Investors Weigh In On Medicus Pharma
Hedge funds and other institutional investors have recently bought and sold shares of the business. Interchange Capital Partners LLC acquired a new position in Medicus Pharma in the 4th quarter valued at about $3,628,000. Armistice Capital LLC acquired a new position in Medicus Pharma in the 1st quarter valued at about $4,710,000. Finally, Private Advisor Group LLC acquired a new position in Medicus Pharma in the 1st quarter valued at about $211,000.
Medicus Pharma Company Profile
(
Get Free Report)
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
See Also
Before you consider Medicus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicus Pharma wasn't on the list.
While Medicus Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
